Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Autor: Miguel, Jesús F San, Richardson, Paul G., Orlowski, Robert Z., Goldschmidt, Hartmut *, Corzo, Deyanira *, Satler, Carol *, Esseltine, Dixie-Lee, Neuwirth, Rachel *, Ponsillo, Maria *, Cakana, Andrew Z *, King, Jay *, Deraedt, William M *, Desai, Avinash *, Lutska, Yana *, Gifkins, Dina *, Liu, Kevin *, Sonneveld, Pieter
Zdroj: In Blood 18 November 2011 118(21):2933-2933
Databáze: ScienceDirect